Rise and shine, everyone, another busy day is on the way. Most days are quite busy now, though, wouldn’t you say? After all, a pandemic is not a regular occurrence, at least we hope. So we will choose to look on the sunny side and brew another cup of stimulation — maple bourbon is our choice this morning — as we prepare to tackle our growing to-do list. Meanwhile, here are a few items of interest to help you sort out your own priorities. Hope your day goes well and, of course, do stay safe. …

A leading think tank aligned with the Democratic Party is laying the groundwork for an aggressive slate of efforts to lower drug prices that could be implemented almost immediately should Joe Biden defeat President Trump in November, STAT says. The Center for American Progress suggested the first-ever use of a monopoly-busting mechanism known as “march-in-rights” to crack down on companies that overcharge for medicines, and resurrecting an Obama-era proposal to change how Medicare pays for many drugs administered by doctors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy